BSEM: Small Cap Eyes NASDAQ Uplisting 👀

*this email contains promotional content from BioStem Technologies, Inc.

BSEM IS IGNITING A NEW ERA IN MEDTECH: EXPLOSIVE GROWTH, 97% MARGINS, AND A NASDAQ UPLIST THAT COULD REWRITE THE SMALL-CAP PLAYBOOK! 

ON TOP ALERT: BioStem Technologies, Inc. (BSEM)

There are a few good reasons to have BSEM at the top of your radar right now.

• Seven Straight Profitable Quarters. 

• A Transformational $40M Acquisition. 

• A High-Stakes Pivot into Hospital Care. 

• A Fast-Track to Nasdaq.

Why the Regenerative Medicine Boom Is Creating Massive Winners— And Why BSEM Is Breaking Away from the Pack

The regenerative medicine and advanced wound care industry is undergoing a powerful shift. Healthcare systems are under pressure to do more with less—deliver better patient outcomes while aggressively cutting long-term costs. Chronic wounds, especially diabetic foot ulcers, represent a multi-billion-dollar burden in the U.S., and the demand for faster, clinically proven healing solutions has never been higher.

In a space crowded with early-stage, cash-burning biotech names, BioStem Technologies, Inc. (BSEM) is doing something rare—executing. 

Profitably. At scale. With clinical validation to back it up!!

Now, with a game-changing acquisition, expanding market reach, and a highly anticipated Nasdaq uplisting on deck, BSEM is rapidly transforming from an under-the-radar small cap into a what could be a serious MedTech contender.

TRANSFORMATIONAL $40M ACQUISITION SUPERCHARGES GROWTH

BSEM didn’t ease into 2026—it came out swinging.

The company’s acquisition of BioTissue Holdings’ surgical and wound care business (valued at up to $40M) is a defining moment. This isn’t just expansion—it’s a full-scale evolution.

What is happening?

Immediate access to hospital systems, outpatient centers, and surgical facilities

Addition of proven products like Neox® and Clarix®

Entry into high-acuity markets: burns, trauma, surgical wounds, soft-tissue repair

$29M in acquired 2025 revenue.

This instantly diversifies BSEM’s revenue streams and positions it far beyond its legacy physician-office model. Even more powerful? A built-in national sales force accelerating penetration into these new channels.

PROFITABILITY THAT DEMANDS ATTENTION: 97% MARGINS & COUNTING

While competitors struggle to break even, BSEM is stacking wins:

• 7 consecutive profitable quarters

• ~$10M quarterly revenue

• Gross margins up to an eye-popping 97%

• $3.4M positive adjusted EBITDA

• ~$16M cash post-acquisition

Yes, recent results showed a GAAP loss—but driven largely by one-time charges and reimbursement shifts. Strip out the noise, and the core business remains highly profitable and scalable.

CLINICAL FIREPOWER: BIORETAIN® IS A GAME-CHANGER

At the heart of BSEM’s edge is its proprietary BioREtain® technology—and it’s not just marketing hype.

53% complete wound closure rate vs. 31% standard of care!

That’s a massive clinical delta.

Add in advanced Bayesian statistical modeling (aligned with FDA-preferred approaches), and BSEM is operating at a level rarely seen in small-cap regenerative medicine.

Translation: Doctors trust it. Payors notice it. Adoption follows.

A $300M+ MARKET OPPORTUNITY—AND BSEM IS ALREADY GAINING SHARE

The runway is massive:

• U.S. diabetic wound care = $9B–$13B annual burden

• BSEM target market = $300M–$350M

• 40% year-over-year unit growth

And traction is real:

• Department of Veterans Affairs

• State Medicaid programs (including Texas)

• Hospitals & ambulatory surgical centers

Now, with expanded capabilities from the BioTissue deal, BSEM is positioned to attack higher-value segments at scale.

THE BIG CATALYST: NASDAQ UPLISTING IN 2026

This is where things get exciting.

BSEM is actively preparing for a Nasdaq uplisting, with audits underway by KPMG, SEC engagement in progress, and financials being institutionalized.

Why it matters:

• Liquidity surge

• Institutional capital inflow

• Higher valuation multiples

• Major visibility upgrade

For many small caps, uplisting is a milestone.

ANALYSTS SEE DISCONNECT: $25.50 PRICE TARGET

According to Zacks Small Cap Research, BSEM’s current valuation doesn’t reflect 1. Proven profitability 2. Elite-level margins 3. Clinical validation 4. Rapid commercial expansion

Their target? $25.50

As the company transitions to a larger exchange and scales its hospital presence, that gap could close—fast.

BOTTOM LINE: BSEM IS NO LONGER EMERGING—IT’S ARRIVING

BSEM is not another speculative biotech.

It’s a revenue-generating, margin-rich, clinically validated MedTech company that just expanded into high-value care settings, acquired meaningful revenue overnight, maintains elite profitability metrics, and is now charging toward a Nasdaq uplisting.

Few small-cap names can check all those boxes.

BSEM is building momentum on every front—and 2026 could be the year the market finally catches up.

FINAL TAKE: WATCH THIS NAME CLOSELY!!!